Editorial

You have full text access to this OnlineOpen article

Of mice and men, calcineurin inhibitors and hepatitis C^†

Alleluiah Rutebemberwa¹,
Hugo R. Rosen^{1,2,3,4,‡,*}

Article first published online: 21 DEC 2011

DOI: 10.1002/lt.22458

Issue

Liver Transplantation

Volume 18, Issue 1, pages 1–4, January 2012

Additional Information

How to Cite

Rutebemberwa, A. and Rosen, H. R. (2012), Of mice and men, calcineurin inhibitors and hepatitis C. Liver Transpl, 18: 1–4. doi: 10.1002/lt.22458

Author Information

¹
Division of Gastroenterology and Hepatology Hepatitis C Center, Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO
²
Liver Transplantation, Hepatitis C Center, Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO
³
Eastern Colorado VA, Denver, CO
⁴
Integrated Program in Immunology, National Jewish Hospital, Denver, CO

^‡
Telephone: 303-724-1858; FAX: 303-724-1891

Email: Hugo R. Rosen (hugo.rosen@ucdenver.edu)

^*Division of Gastroenterology and Hepatology (B-158), Department of Medicine, University of Colorado Health Sciences Center, 12631 East 17th Avenue, Academic Office Building 1, Room 7614, P.O. Box 6511, Aurora, CO 80045

^†
See Article on Page 38
^‡
Telephone: 303-724-1858; FAX: 303-724-1891

Publication History

Issue published online: 21 DEC 2011
Article first published online: 21 DEC 2011
Accepted manuscript online: 27 OCT 2011 07:26AM EST
Manuscript Received: 17 OCT 2011
Manuscript Accepted: 17 OCT 2011

ARTICLE TOOLS

View Full Article (HTML) Get PDF (79K)

REFERENCES

1
Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000; 30: 125-143.
2
Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21.
- CrossRef,
- PubMed
3
Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-2438.
4
Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14( suppl 2): S36-S44.
Direct Link:
5
Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009; 15: 126-135.
Direct Link:
6
Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008; 14( suppl 2): S58-S66.
Direct Link:
7
Hughes MG Jr, Rosen HR. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009; 15: 1395-1411.
Direct Link:
8
Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006; 12( suppl 2): S38-S47.
Direct Link:
9
Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5( suppl 1): S107-S114.
10
Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 2008; 134: 1789-1801.
11
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
12
Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006; 80: 4510-4520.
13
Hirano K, Ichikawa T, Nakao K, Matsumoto A, Miyaaki H, Shibata H, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin A, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292-298.
Direct Link:
14
Pan Q, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tilanus HW, Janssen HL, van der Laan LJ. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. Liver Transpl 2010; 16: 520-526.
- PubMed,
- Web of Science® Times Cited: 2
15
Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004; 39: 1469-1475.
Direct Link:
16
Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004; 78: 13779-13792.
17
Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-365.
18
Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 2005; 86( pt 8): 2185-2196.
19
Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.
20
Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 622-634.
21
Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456.
22
Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991; 66: 245-256.
23
Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847-856.
Direct Link:
24
Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912.
25
Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103: 3805-3809.
26
Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 2006; 43: 1346-1353.
Direct Link:
27
Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007; 581: 1983-1987.
28
Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007; 45: 921-928.
Direct Link:
29
Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993; 7: 2298-2307.
30
Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995; 10: 453-460.
31
Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, et al. Robust expansion of human hepatocytes in Fah^−/−/Rag2^−/−/Il2rg^−/− mice. Nat Biotechnol 2007; 25: 903-910.
32
Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-930.
33
Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344.
34
Kneteman NM, Asthana S, Lewis J, Dibben C, Douglas D, Nourbakhsh M, et al. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl 2011; 18:38–44.
35
Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-298.
Direct Link:
36
Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-572.
37
Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-57.
Direct Link:
38
Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209.
39
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
Direct Link:

View Full Article (HTML) Get PDF (79K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Of mice and men, calcineurin inhibitors and hepatitis C^†

Liver Transplantation

How to Cite

Author Information

Publication History

ARTICLE TOOLS

REFERENCES

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Of mice and men, calcineurin inhibitors and hepatitis C†

Liver Transplantation

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

REFERENCES

More content like this

Of mice and men, calcineurin inhibitors and hepatitis C^†